Pharmaceutical Technology on MSN
Recursion CEO details novel Phase III endpoint for rare disease drug
The AI-driven biotech has secured FDA alignment on a pivotal trial for its FAP therapy, with a study start planned for 2027.
Recursion Pharmaceuticals (NASDAQ:RXRX) has aligned with the U.S. Food and Drug Administration on the primary endpoint for a planned Phase III study of its experimental treatment for familial ...
On Nov. 18, 2026, Recursion shares climbed after regulators aligned on its lead familial adenomatous polyposis trial, though ...
Recursion Pharmaceuticals, Inc. ( RXRX) announced Wednesday that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the design of its registrational Phase 3 trial of REC-4881 ...
Recursion Pharmaceuticals said on November 18, 2026 that it had aligned with the U.S. Food and Drug Administration on a ...
Recursion announces FDA alignment for REC-4881’s Phase 3 trial in familial adenomatous polyposis, targeting crucial adenoma excision outcomes.
The discovery by security company Calif shows A.I.’s ability to find gaping security holes in popular software. The Java flaw ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
In the field of artificial intelligence, machine learning is a branch that uses data and algorithms to imitate human learning. It's an ongoing process in which computers can improve their accuracy ...
RXRX is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of RXRX shares has decreased $0.27 since the market last closed. This is a 9.93 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results